Home / Market News / $PACB
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Piper Sandler Maintains Neutral Rating on PacBio, Raises Price Target

Nov 6, 2026, 2:09 PM UTC · Primary ticker $PACB

Piper Sandler maintained a Neutral rating on PacBio but increased its price target by 50% from $2.00 to $3.00. This suggests a modest positive outlook from the analyst, implying a potential 17.6% upside from the stock's recent closing price.

Piper Sandler, a prominent investment bank, updated its coverage on Pacific Biosciences of California, Inc. (PacBio). While maintaining a 'Neutral' rating, the firm significantly raised its price target for PACB stock from $2.00 to $3.00, representing a 50% increase. This adjustment implies a potential upside of 17.6% from the stock's closing price on November 4, 2026. This news is moderately positive for PacBio as it signals increased confidence from an analyst, potentially attracting more investor interest. For traders, this could lead to short-term buying activity, but the 'Neutral' rating suggests that significant long-term upside might still be limited without further fundamental improvements.

$PACB positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.